Analysts See $-0.05 EPS for Ritter Pharmaceuticals, Inc. (RTTR)

February 20, 2018 - By Michael Pereira

 Analysts See $ 0.05 EPS for Ritter Pharmaceuticals, Inc. (RTTR)

Analysts expect Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) to report $-0.05 EPS on February, 26.They anticipate $0.69 EPS change or 93.24 % from last quarter’s $-0.74 EPS. After having $-0.14 EPS previously, Ritter Pharmaceuticals, Inc.’s analysts see -64.29 % EPS growth. The stock decreased 1.27% or $0.004 during the last trading session, reaching $0.312. About 50,886 shares traded. Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) has declined 56.21% since February 20, 2017 and is downtrending. It has underperformed by 72.91% the S&P500.

Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) Ratings Coverage

Among 5 analysts covering Ritter Pharmaceuticals (NASDAQ:RTTR), 4 have Buy rating, 0 Sell and 1 Hold. Therefore 80% are positive. Ritter Pharmaceuticals had 9 analyst reports since December 2, 2015 according to SRatingsIntel. The company was initiated on Wednesday, January 4 by Rodman & Renshaw. Roth Capital maintained Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) rating on Monday, June 5. Roth Capital has “Buy” rating and $3.5000 target. The firm has “Buy” rating by H.C. Wainwright given on Monday, October 23. Chardan Capital Markets maintained it with “Buy” rating and $3.30 target in Tuesday, October 25 report. On Friday, August 4 the stock rating was maintained by Maxim Group with “Hold”. The firm has “Hold” rating by Maxim Group given on Wednesday, July 5. The stock of Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) has “Buy” rating given on Thursday, April 14 by Maxim Group. The rating was initiated by Chardan Capital Markets on Wednesday, December 2 with “Buy”.

Ritter Pharmaceuticals, Inc., a specialty pharmaceutical company, develops novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. The company has market cap of $15.45 million. The Company’s lead product candidate is RP-G28, a novel microbiome modulator, which has completed Phase 2b/3 clinical trial for the reduction of symptoms associated with lactose intolerance. It currently has negative earnings. The company's product, RP-G28 is designed to stimulate the growth of lactose-metabolizing bacteria in the colon, thereby adapting the gut microbiome to assist in digesting the lactose that reaches the large intestine.

More notable recent Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) news were published by: Marketwired.com which released: “Ritter Pharmaceuticals, Inc. Announces End of Phase 2 Meeting with the FDA and …” on April 12, 2017, also Globenewswire.com with their article: “Ritter Pharmaceuticals Appoints Distinguished Gastroenterologist, William Chey …” published on February 20, 2018, Globenewswire.com published: “Ritter Pharmaceuticals, Inc. Prices $23000000 Public Offering” on September 29, 2017. More interesting news about Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) were released by: Valuewalk.com and their article: “MabVax Therapeutics Holdings, Inc. (MBVX) reports 4.99% activist investor …” published on February 14, 2018 as well as Globenewswire.com‘s news article titled: “Ritter Pharmaceuticals Appoints Diane J. Plotkin as Vice President of Clinical …” with publication date: January 29, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: